Alnylam Pharmaceuticals, Inc (ALNY) CEO John Maraganore on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/06/20
Alnylam Pharmaceuticals Reports Second Quarter 2020 Financial Results and Highlights Recent Period ActivityBusiness Wire • 08/06/20
Alnylam Submits CTA Application for ALN-HSD, an Investigational RNAi Therapeutic for the Treatment of Nonalcoholic Steatohepatitis (NASH)Business Wire • 08/03/20
Alnylam to Webcast Conference Call Discussing Second Quarter 2020 Financial ResultsBusiness Wire • 07/23/20
Alnylam Announces that the United Kingdom’s MHRA Grants Early Access to LumasiranBusiness Wire • 07/13/20
Alnylam Pharmaceuticals and Taiba Group Partner to Commercialize RNAi Therapeutics in the Gulf StatesBusiness Wire • 07/08/20
Alnylam Reports New 12-Month Interim Data From the ENVISION Phase 3 Study of Givosiran in Acute Hepatic PorphyriaBusiness Wire • 06/30/20
Clinical Data Reaffirm That Lumasiran Will Almost Certainly Be Alnylam's Third Commercial ProductSeeking Alpha • 06/08/20
Alnylam Pharmaceuticals, Inc. (ALNY) CEO Howard Lutnick on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/06/20